EGFR and prostate carcinoma: In ovarian cancer, overexpressed WFDC2 is associated with the proliferation, metastasis, and invasion of it, attributed to the change of PI3K/AKT and JAK/STAT3 signaling pathwaysIn prostate cancer, WFDC2 inhibits prostate cancer metastasis by inhibiting the activation of EGFR